



Legislative & Regulatory Briefing

RECENT DEVELOPMENTS FROM YOUR STATE AND FEDERAL GOVERNMENTS

SEPTEMBER 2022

AMCP Submits Comments to Improve the Medicare Advantage Program

On Aug. 1, the Centers for Medicare and Medicaid Services (CMS) released a Request for Information (RFI) soliciting public comment on ways to improve the Medicare Advantage program. The RFI sought feedback that aligned with the agency's Vision for Medicare. This includes solutions that would advance health equity, drive person-centered care, and increase stakeholder engagement. On Aug. 31, AMCP submitted comments referencing data collection techniques and formulary management practices that address health disparities. AMCP's comments also encourage the adoption of standardized pharmacy performance measures, as well as a unified framework around value-based purchasing agreements, to promote person-centered care within the Medicare Advantage program.

[Read the full comment letter.](#)



**A MULTIDIMENSIONAL
OPTION**

[LEARN MORE](#)

sanofi

Please click here for full Prescribing Information.

MAT-US-2203688-v1.0-07/2022

New Member Benefit! Regulatory NewsBREAKS

AMCP unveiled the first Regulatory NewsBREAK on Sept. 16. As a new benefit to members, the Regulatory NewsBREAK will be released in response to newly enacted regulations or recently issued sub-regulatory guidance. The inaugural Regulatory NewsBREAK summarized three CMS guidance memorandums addressing the implementation of the Inflation Reduction Act's (IRA) adult vaccine, insulin, and Part D Senior Savings (PDSS) model provisions. Read the first NewsBREAK today.

[ACCESS TODAY](#)

Eye On Washington

AMCP Joins Request for PREP Act Declaration for Pharmacist Prescribing of Monkeypox Treatments

AMCP joined with 13 other pharmacy organizations in a letter to the Department of Health and Human Services (HHS), calling on HHS to issue a Public Readiness and Emergency Preparedness (PREP) Act declaration for pharmacists to prescribe FDA-approved monkeypox treatments. Currently, 12 states and the District of Columbia lack clear authority or restrict the ability of

Advocacy Tip

Stay up-to-date: Read AMCP's [Letters, Statements and Analysis](#) on all legislation and regulation impacting managed care pharmacy.

pharmacists to administer monkeypox vaccines, testing, and therapeutics. The letter, dated Aug. 19, positions pharmacists as the country's most accessible healthcare providers, who educate and vaccinate the roughly 90% of Americans who live within five miles of a pharmacy. This accessibility allowed pharmacists to administer over 266 million doses of the COVID-19 vaccine under a similar PREP Act declaration for the COVID-19 Public Health Emergency (PHE). The letter also urges HHS to coordinate with payers to ensure adequate reimbursement for these services when provided by pharmacists.

[Read the sign-on letter.](#)

Request for Information: Make Your Voice Heard


On Sept. 6, CMS released an RFI soliciting public comment on ways to reduce burden, promote efficiency, and advance equity within the Agency's programs. Through the RFI, CMS seeks to gather information on healthcare accessibility challenges, provider experiences, advancements in health equity, and the impact of COVID-19 waivers and flexibilities provided as part of the coronavirus PHE. CMS intends to use the comments provided to identify opportunities for increased innovation and efficiency across CMS policies, programs, and practices. Unlike previous RFIs, which traditionally accept comments through the Federal Register, this RFI uses a web-based public comment form designed for ease of access and improved user experience. AMCP intends to submit comments before the deadline of Nov. 4.

[View the RFI.](#)

ICYMI: August 2022 Legislative and Regulatory Briefing Webinar

On Aug. 23, AMCP's Policy & Government Relations team presented an update on the recent federal and state legislative and regulatory actions pertinent to managed care and specialty pharmacy professionals. Speakers identified the latest legislative developments in Congress along with recent regulations released by the Biden administration. Pressing legislative and regulatory activity from key state governments was also highlighted. At the conclusion of the webinar, the speakers answered questions provided by attendees.

[Watch the webinar recording.](#)



The advertisement banner for Eloctate features a dark blue background with wavy, lighter blue and teal patterns at the top. The product name 'ELOCTATE' is prominently displayed in white, with a small icon of a protein structure to its left. Below the name, the text '[Antihemophilic Factor (Recombinant), Fc Fusion Protein]' is written in a smaller font. The main headline 'A MULTI-DIMENSIONAL OPTION' is centered in large, white, all-caps letters. Below this, a blue button with white text says 'LEARN MORE'. At the bottom of the button, it reads 'Please click here for full Prescribing Information.' The Sanofi logo is positioned at the bottom right, with the alphanumeric code 'MAT-US-2203688-v1.0-07/2022' underneath it.